Acura NanoMedicine Corporation
Update：2025/12/24
Industries
Main Industry
Health Care
Main Product/Service
1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2
Founded Year
2017
Unified Business No.
52805302
Status
Active
Number of Employees
4
Total Paid-in
Capital
25,014,700 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Acura NanoMedicine is one of the few dual-platform technology new drug companies in the world. We integrate AI big data drug discovery platform and nano drug delivery system platform to develop a series of nano anticancer drugs (AN-8 series & others) that
